Septerna, INC 8-K filings

Septerna, Inc. announced its second quarter 2026 financial results and business highlights, reporting a cash position of $516.5 million and ongoing progress in its clinical trials for SEP-479.

Septerna, Inc. announced the election of two new directors and the ratification of Ernst & Young LLP as its independent auditor for the fiscal year 2026 following its annual meeting of stockholders.

Septerna, Inc. announced its first quarter 2026 financial results and business highlights, reporting significant pipeline progress with positive Phase 1 data for SEP-631 and initiation of a Phase 1 trial for SEP-479, while maintaining a strong cash position.

Septerna, Inc. has dosed the first participants in a Phase 1 clinical trial for SEP-479, an oral small molecule agonist for hypoparathyroidism, with data expected in late 2026 or early 2027.

Septerna, Inc. announced positive Phase 1 clinical trial results for SEP-631, an oral drug for mast cell-driven diseases, and outlined its Phase 2 development strategy.

Septerna, Inc. presented updates on its lead GPCR drug programs, including SEP-479 and SEP-631, and highlighted its Novo Nordisk collaboration, projecting a cash runway into 2029.

Septerna, a clinical-stage biotechnology company, announced the appointment of Mark A. Wilson as Chief Legal Officer, bringing over 25 years of legal and intellectual property expertise.

Septerna, Inc. announced robust third-quarter 2025 financial results, significant pipeline progress, and an extended cash runway into at least 2029.

Septerna, Inc. announced the appointment of Dr. Keith Gottesdiener, a seasoned biotechnology executive, to its Board of Directors, expanding the board to eight members.

Septerna, Inc. updated its corporate presentation, highlighting pipeline progress for oral small molecule GPCR therapies, including new clinical trial initiations and a significant collaboration with Novo Nordisk, extending its cash runway into 2029.

Septerna, Inc. announced the dosing of the first participants in its Phase 1 clinical trial for SEP-631, an oral small molecule targeting mast cell-driven diseases like chronic spontaneous urticaria.

Septerna, Inc. reported Q2 2025 financial results, highlighted pipeline progress, and announced a significant cash runway extension into 2029 following a $195 million upfront payment from Novo Nordisk.

Septerna, Inc. announced the appointment of Liz Bhatt, current Chief Operating Officer, to the additional role of President, effective August 1, 2025.

Septerna, Inc. announced that its previously disclosed Collaboration and License Agreement with Novo Nordisk A/S has become effective after receiving early termination of the Hart-Scott-Rodino waiting period.

Septerna, Inc. announced the successful election of two Class I directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Septerna announces a major collaboration with Novo Nordisk potentially worth $2.2 billion and reports its first quarter 2025 financial results, highlighting progress in its GPCR-targeted programs.

Septerna and Novo Nordisk have entered into a global collaboration and license agreement potentially worth over $2.2 billion to develop oral small molecule therapies for metabolic-related diseases.

Septerna, Inc. announces its Q4 and full year 2024 financial results, highlighting preclinical advancements and upcoming milestones, including plans to select a next-generation oral small molecule PTH1R agonist and initiate a Phase 1 trial for SEP-631 in 2025.

Septerna, Inc. presents at the TD Cowen 45th Annual Health Care Conference, showcasing its Native Complex Platform for GPCR drug discovery and its portfolio of oral small molecule programs.

Septerna discontinues its Phase 1 clinical trial of SEP-786 due to unexpected safety events and plans to advance a next-generation PTH1R agonist.

Septerna, Inc. presented at the J.P. Morgan Healthcare Conference, showcasing its pipeline of oral small molecule GPCR-targeted programs and its Native Complex Platform for drug discovery.

Septerna, Inc. has appointed Gil Labrucherie as its new Chief Financial Officer, effective January 6, 2025.

Septerna, a clinical-stage biotech company, announced its Q3 2024 financial results, highlighted by the ongoing Phase 1 clinical trial for SEP-786 and a strong cash position following its IPO.

Septerna Inc. completes its initial public offering (IPO) and files amended and restated certificate of incorporation and bylaws.